Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

$24.99

Analysis of Liquidity Ratios
Quarterly Data

Microsoft Excel

Liquidity Ratios (Summary)

AbbVie Inc., liquidity ratios (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Current ratio
Quick ratio
Cash ratio

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The overall liquidity position is characterized by a pattern of initial stability, a significant downturn starting in mid-2024, and a gradual recovery entering 2026. Across the entire period, all primary liquidity metrics remain below 1.0, signifying that current liabilities consistently exceed current assets.

Current Ratio
The current ratio fluctuated between a peak of 0.96, maintained across several quarters between September 2022 and September 2023, and a low of 0.65 in September 2024. A period of relative stability was observed through early 2024 before a sharp decline occurred during the second and third quarters of that year. A moderate recovery trend is evident from early 2025, culminating in a ratio of 0.80 by March 2026.
Quick Ratio
A consistent gap is maintained between the current and quick ratios, reflecting the impact of non-quick current assets on overall liquidity. The ratio reached a peak of 0.72 in March 2024 but experienced a substantial contraction to 0.41 by December 2025. Similar to the trend seen in the current ratio, a rebound is noted in the first quarter of 2026, returning the ratio to 0.52.
Cash Ratio
The cash ratio exhibits the highest degree of volatility, reaching a peak of 0.44 in March 2024. Following this peak, a precipitous decline occurred throughout 2024 and 2025, reaching a period low of 0.12 in December 2025. This indicates a significant reduction in immediate cash availability relative to current liabilities before a recovery to 0.22 in March 2026.

The synchronized decline across all three ratios during 2024 and 2025 suggests a period of increased short-term obligations or a strategic reallocation of liquid assets. The convergence of these metrics at their lowest points in late 2025, followed by a simultaneous uptick in early 2026, points toward a cyclical shift in the short-term financial positioning.


Current Ratio

AbbVie Inc., current ratio calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Current assets
Current liabilities
Liquidity Ratio
Current ratio1
Benchmarks
Current Ratio, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The liquidity profile of the organization is characterized by a current ratio that remained consistently below 1.0 throughout the analyzed period from March 2022 to March 2026. This indicates a persistent working capital deficit where current liabilities exceeded current assets across all reporting quarters.

Current Ratio Volatility
The current ratio exhibited three distinct phases. An initial improvement phase occurred between March 2022 and December 2022, where the ratio rose from 0.82 to 0.96. This was followed by a period of relative stability through March 2024, maintaining a range between 0.81 and 0.96. A significant decline was observed starting in June 2024, with the ratio reaching a period low of 0.65 in September 2024 and remaining suppressed below 0.80 until a slight recovery to 0.80 in March 2026.
Current Liabilities Trajectory
There is a clear upward trend in current liabilities over the long term. Obligations increased from 32,521 million USD in March 2022 to a peak of 43,289 million USD in December 2025. The most aggressive expansion of liabilities occurred between March 2024 and September 2024, contributing heavily to the deterioration of the liquidity ratio during that window.
Current Asset Fluctuations
Current assets demonstrated significant volatility rather than a linear trend. Assets peaked at 38,871 million USD in March 2024, but subsequently contracted sharply to 25,582 million USD by December 2024. This contraction, occurring simultaneously with rising liabilities, resulted in the lowest recorded liquidity levels. A modest recovery in asset levels followed in 2025 and early 2026, ending at 33,529 million USD.
Liquidity Correlation
The divergence between asset and liability growth reached its maximum point in the latter half of 2024 and throughout 2025. The pressure on the current ratio was most acute when liabilities climbed above 40,000 million USD while assets failed to maintain a commensurate level of growth, suggesting a period of heightened reliance on short-term financing or operational cash flow to meet immediate obligations.

Quick Ratio

AbbVie Inc., quick ratio calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Cash and equivalents
Accounts receivable, net
Total quick assets
 
Current liabilities
Liquidity Ratio
Quick ratio1
Benchmarks
Quick Ratio, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The liquidity position experienced significant volatility between March 2022 and March 2026, characterized by a period of strengthening followed by a notable contraction and a subsequent partial recovery.

Quick Ratio Trend Analysis
The quick ratio demonstrated an upward trajectory from March 2022, rising from 0.52 to a peak of 0.72 by March 2024. This period represents the strongest liquidity phase within the observed timeframe. However, a sharp decline occurred thereafter, with the ratio falling to 0.43 by September 2024 and reaching a nadir of 0.41 in December 2025. By March 31, 2026, the ratio recovered to 0.52, returning to its initial 2022 baseline.
Quick Assets Dynamics
Total quick assets showed substantial growth in the first half of the period, climbing from 16,831 million USD in March 2022 to a maximum of 30,016 million USD in March 2024. A rapid depletion of these assets followed, with levels dropping to 16,443 million USD by December 2024. Throughout 2025, quick assets remained relatively suppressed, fluctuating between 17,652 million USD and 19,104 million USD, before increasing to 21,870 million USD in the final quarter.
Current Liabilities Evolution
Current liabilities remained relatively stable between 27,590 million USD and 34,773 million USD from March 2022 through September 2023. A structural increase in obligations began in March 2024, with liabilities rising above 41,000 million USD and peaking at 43,289 million USD in December 2025. The simultaneous increase in liabilities and the decrease in quick assets during 2024 and 2025 exerted significant downward pressure on the quick ratio.
Liquidity Correlation and Insights
The divergence between asset levels and liability obligations became most acute between March 2024 and December 2025. The contraction of the quick ratio during this window suggests a reduced capacity to meet short-term obligations using only the most liquid assets. The recovery observed in March 2026 is primarily attributable to a rise in total quick assets to 21,870 million USD coupled with a slight reduction in current liabilities to 42,100 million USD.

Cash Ratio

AbbVie Inc., cash ratio calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Cash and equivalents
Total cash assets
 
Current liabilities
Liquidity Ratio
Cash ratio1
Benchmarks
Cash Ratio, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The liquidity profile demonstrates a period of significant volatility, characterized by a strong upward trajectory in the cash ratio through early 2024, followed by a pronounced contraction and a subsequent partial recovery in early 2026.

Total Cash Asset Trends
Cash reserves exhibited substantial fluctuations over the analyzed timeframe. Assets increased from 6,098 million in March 2022 to a peak of 18,067 million in March 2024. A sharp decline followed, with cash positions dropping to a low of 5,175 million by March 2025, before rebounding to 9,391 million by March 2026.
Current Liability Progression
A consistent long-term increase in current liabilities is observed. Short-term obligations rose from 32,521 million in March 2022 to a peak of 43,289 million in December 2025. This steady growth in liabilities exerted downward pressure on liquidity ratios, particularly during periods of declining cash balances.
Cash Ratio Dynamics
The cash ratio peaked at 0.44 in March 2024, indicating the strongest immediate liquidity position within the period. However, a sustained decline occurred throughout the remainder of 2024 and 2025, reaching a minimum of 0.12 in December 2025. This deterioration was driven by the simultaneous reduction in cash assets and the expansion of current liabilities. By March 31, 2026, the ratio recovered to 0.22, reflecting an improved ability to meet short-term obligations compared to the 2025 lows.